Maze Therapeutics, Inc. Common Stock (MAZE) — Cash Flow-to-Debt Ratio
Maze Therapeutics, Inc. Common Stock (MAZE) has a Cash Flow-to-Debt Ratio of -0.50x as of March 2026, meaning its operating cash flow of $-39.11 Million could theoretically repay -1% of its total liabilities ($78.01 Million) in one year. Explore investment intensity of Maze Therapeutics, Inc. Common Stock to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Maze Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio (2022–2025)
Historical debt coverage capacity for Maze Therapeutics, Inc. Common Stock across 4 annual periods. Also explore how large is Maze Therapeutics, Inc. Common Stock's balance sheet for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Maze Therapeutics, Inc. Common Stock (2022–2025)
Year-by-year debt coverage analysis for Maze Therapeutics, Inc. Common Stock. For market capitalisation and broader financial context, see MAZE stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.66x | $-111.94 Million | $42.16 Million | ▼ -252.5% |
| 2024 | 1.74x | $75.95 Million | $43.64 Million | ▲ +223.2% |
| 2023 | -1.41x | $-86.83 Million | $61.45 Million | ▲ +30.9% |
| 2022 | -2.04x | $-99.20 Million | $48.51 Million | — |